MGI(SH:688114) Xin Lang Cai Jing·2026-01-05 07:18Group 1 - The core viewpoint of the news is that BGI Genomics has seen a stock price increase of 5.13%, reaching 63.88 CNY per share, with a total market capitalization of 26.607 billion CNY as of the report date [1] - BGI Genomics, established on April 13, 2016, and listed on September 9, 2022, focuses on the life sciences and biotechnology sectors, with 90.89% of its revenue coming from the sales of instruments, reagents, and consumables [1] - The company has a revenue composition of 90.89% from sales of instruments and consumables, 7.10% from services, and 2.01% from other sources [1] Group 2 - From the perspective of fund holdings, Guolian Fund has a significant position in BGI Genomics, with its Guolian Medical Health Mixed A fund holding 40,500 shares, representing 9.25% of the fund's net value [2] - The Guolian Medical Health Mixed A fund has a total scale of 8.3061 million CNY and has achieved a year-to-date return of 11.44%, ranking 5616 out of 8155 in its category [2] - The fund has a cumulative return of 25.67% since its inception on September 19, 2018 [2] Group 3 - The fund manager of Guolian Medical Health Mixed A is Liu Baichuan, who has been in the position for 345 days, managing assets totaling 30.2729 million CNY [3] - During Liu Baichuan's tenure, the best fund return was 14.38%, while the worst was 14.12% [3]